Research Use Only vs Compounded Peptides: What the Label Means Legally

A “research use only” vial and a compounded peptide can contain the same molecule, but the law treats them as different products. The research-only label is the wording of a narrow federal exemption for shipping a drug to laboratories, and FDA has repeatedly said the label does not protect a seller whose website shows the product is meant for people.^[2][4] A compounded peptide is made by a state-licensed pharmacy on a prescription written for one patient. Since October 28, 2026, HHS has said it does not intend to take enforcement action against 503A pharmacies that compound six peptides under ten conditions.^[1] Neither kind of product is FDA-approved.

What “research use only” means under federal rules

The phrase has a real legal home. A federal regulation, 21 CFR 312.160, lets a company ship an unapproved drug “intended solely for tests in vitro or in animals used only for laboratory research purposes” if the package carries a set caution: “Contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans.”^[2]

That permission comes with duties. The shipper must use due diligence to make sure the buyer “is regularly engaged in conducting such tests” and that the drug will be used that way. It must keep records of the name and address of the expert who received each shipment, with dates, quantities and batch numbers, for two years. FDA can end the permission if the drug is used for anything other than bona fide scientific investigation.^[2] A checkout page open to anyone who ticks a box saying they are a researcher does not show that kind of diligence.

The second rule that matters is how FDA decides what a product is for. Under 21 CFR 201.128, “intended use” means the objective intent of whoever is responsible for the labeling, and that intent can be shown by labeling claims, advertising, or what the seller says in writing or out loud.^[3] A disclaimer on the vial is one piece of evidence. The product pages, the blog posts, the dosing help and the accessories sold beside it are evidence too.

What FDA’s warning letters say about the label

FDA’s letters to online peptide sellers follow the same pattern. In December 2024 it told Summit Research Peptides that “despite statements on your product labeling marketing your products as ‘RESEARCH USE ONLY’ and ‘INTENDED AS A RESEARCH CHEMICAL ONLY,’” its websites showed the products were “intended to be drugs for human use.”^[4] In March 2026 it wrote nearly the same sentence to Gram Peptides, whose labels said “not intended for human consumption, medical use, or veterinary use.”^[5] FDA then treated the products as unapproved new drugs, and shipping them across state lines as a violation of the Food, Drug, and Cosmetic Act.^[4][6]

The August 24, 2026 letters go a step further and treat the accessories as evidence. FDA told Peak Performance Peptides that by selling bacteriostatic water as a solvent for its vials it was “providing the means to prepare an injectable drug for human administration,” and that selling the two together made the water a drug as well.^[6] Royal Peptides was cited for offering bacteriostatic water alongside a “peptide guide” and a “peptide calculator.”^[7] Those letters named GLP-1 drugs sold as research peptides along with SS-31, PT-141 and tesamorelin.^[6][7]

Our FDA warning-letter tracker holds 8 letters, dated between December 2024 and March 2026, in which FDA quotes the seller’s research-only or not-for-human label and then sets it aside. That is a floor, since the tracker stores excerpts and some letters make the point in a footnote. FDA’s consumer page on GLP-1 drugs puts it plainly: products “falsely labeled” for research or not for human consumption “have been sold directly to consumers for human use with dosing instructions,” and FDA urges people not to buy them.^[8] The letters themselves are collected in FDA warning letters to peptide sellers.

FDA cited one seller for selling bacteriostatic water next to a “peptide guide” and a “peptide calculator.”

What makes a peptide “compounded” under the October 2026 policy

Compounding is a pharmacy making a drug for an individual patient from raw ingredients. Under section 503A of the Act, that drug must be made on a valid patient-specific prescription, and it is not FDA-approved.^[9] HHS says so in the policy itself: “Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed.”^[1]

On October 28, 2026, HHS said it does not intend to take enforcement action against a state-licensed pharmacy, a federal facility or a licensed physician that compounds BPC-157, TB-500, epitalon, Semax, KPV or MOTS-c, as long as every condition in the policy is met.^[1] The policy names the research market as its target. HHS wrote that it means to “discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients” and to give patients “a more controlled alternative.”^[1] It covers 503A pharmacies only, not the larger 503B outsourcing facilities.^[10] What each condition requires is set out in the HHS peptide compounding policy, and the two pharmacy types are compared in 503A vs 503B pharmacies.

The conditions that a patient can see, or ask about, are these:

• A prescription for you. The drug must meet the 503A patient-specific prescription requirement.^[1]
• A traceable ingredient. The bulk peptide must come from an FDA-registered facility with a valid certificate of analysis covering identity, purity, potency and contaminants, and the original maker’s facility location must be on that certificate.^[1]
• One peptide per product. The product may contain only a single active ingredient from the list, so blends are outside the policy (see blends and stacks).^[1]
• The allowed route. Each peptide is limited to set routes. Semax is intranasal only, KPV topical or oral only, and TB-500, epitalon and MOTS-c injectable only. An oral product must come with the pharmacy’s documentation that the formulation reaches “an adequate level of oral bioavailability in humans” (see oral BPC-157 capsules).^[1]
• A fixed label line. The labeling must state “This is a compounded drug product. Not for resale.”^[1]
• A way to report problems. The pharmacy reports serious adverse events and quality problems to FDA’s MedWatch program and to the states, and the patient labeling should explain how to report them.^[1]
• Only a cleared syringe. The only device packed with the drug may be an FDA 510(k)-cleared syringe.^[1]

The policy is interim. It lasts until each peptide is settled by a final rule on the 503A bulks list, and HHS may revisit it if a safety signal or quality problem appears.^[1] For each of the six, FDA’s drug center had recommended against listing, and the advisory committee had voted in favor.^[1]

Research-use-only vs compounded peptides, side by side

How to tell which one you are looking at

1. Read every label and product page for research wording. “Research use only,” “for laboratory use” or “not for human consumption” anywhere on it means you are not holding a product compounded under the HHS policy, whose label must carry the compounded-drug statement instead.^[1]
2. Ask who prescribed it. If nobody with a license reviewed your case and wrote a prescription in your name, it is not a 503A compounded drug.^[9]
3. Find the pharmacy’s name and look it up. A compounded product comes from a named, state-licensed pharmacy. Our 503A vs 503B guide shows how to check which kind filled it.
4. Check that it is one peptide, on the list, by the allowed route. A BPC-157 and TB-500 vial, an injectable KPV or a GHK-Cu product falls outside the policy. Our peptides hub has a page for each peptide.
5. Look at what comes in the box. Bacteriostatic water, a reconstitution guide or a dose calculator sold with a research-only vial is the pattern FDA has cited in warning letters.^[6][7]
6. Look for reporting instructions. Patient labeling under the policy should tell you how to report a side effect or a problem with the product.^[1]
7. Treat a certificate of analysis as a starting point. Under the policy the certificate belongs to the bulk ingredient and sits with the pharmacy. What a research seller’s PDF can and cannot show is covered in how to read a peptide certificate of analysis.

Is it legal to sell research peptides in the US?

Selling an unapproved peptide for genuine laboratory work, with the required caution, to buyers the shipper has checked, is what 21 CFR 312.160 allows.^[2] Selling the same vial to the public with dosing help is what FDA’s letters describe as introducing unapproved new drugs into interstate commerce.^[4][6] The HHS policy does not change that. It applies to pharmacies and physicians who compound, and it gives no protection to a website that sells research-labeled vials.^[1]

A compounded peptide under the policy has a different kind of legality. HHS has said it does not intend to enforce, on conditions, for now. That is weaker than FDA approval and weaker than a place on the 503A bulks list, and HHS can withdraw it.^[1] A peptide that is not one of the six, such as ipamorelin, CJC-1295 or GHK-Cu, still has no route under it; their status is on are peptides legal?

Common questions